Investor Newsletter

Issue 07 2024

MicroPort®

Firesorb®: The World's Latest Generation of Bioresorbable Cardiac Stent Approved for Market Release, Gains Recognition from Leading Medical Experts for Its Exceptional Clinical Performance

MicroPort® Scientific Corporation (00853.HK) proudly announces that its wholly-owned subsidiary, Shanghai MicroPort® Medical (Group) Co., Ltd. (Shanghai MicroPort®), has received official market approval from the National Medical Products Administration (NMPA) for Firesorb®, the world's first next-generation fully bioresorbable cardiac stent.

During the 18th Oriental Congress of Cardiology and the World Congress of Cardiology (OCC-WCC 2024), Shanghai MicroPort® hosted a product launch event for Firesorb® under the theme "Externalized in Form, Internalized in Heart". The event featured presentations on Firesorb®'s innovative design and clinical trial data to an audience of hundreds of experts and scholars from around the world. The clinical advantages of Firesorb® received widespread recognition and acclaim from leading cardiovascular experts, including Academician Runlin Gao from Fuwai Hospital, Academician Junbo Ge from Zhongshan Hospital affiliated with Fudan University, and Academician Jian'an Wang from the Second Affiliated Hospital of Zhejiang University School of Medicine, along with Professor Lei Song and Professor Jun Jiang.

Dr. ZhaoHua Chang, Chairman and CEO of MicroPort® Scientific Corporation, remarked: "During the initial surge of interest in bioresorbable cardiac stents, Shanghai MicroPort® chose not to hastily follow industry trends. Even during the most challenging periods when several products were withdrawn from the market due to unmet clinical endpoints, we made decisive adjustments to our technical approach, focusing on developing new materials, drug delivery methods, and innovative delivery systems. This perseverance resulted in an ideal product. We hope to continue receiving understanding and support from all sectors of society, including industry peers, as we move forward with the promotion of this new medical solution, embodying the universal medical philosophy that 'The sun and the moon shine on all without neglecting the smallest, and the rain and dew nourish all without disregarding the tiniest'."

MicroPort

MicroPort® NeuroTech™'s NUMEN® Coil Receives Reimbursement Approval in France and Completes Initial Commercial Implantations

MicroPort® NeuroTech™ recently completed the first two commercial implantations of its NUMEN® Coil Embolization System (NUMEN®) in Paris, France. Prior to these procedures, NUMEN® underwent evaluation by France's National Health Authority (HAS) and secured a health insurance reimbursement code. In both cases, NUMEN® demonstrated stable framing ability, strong space-seeking capabilities, good packing density, and a low risk of coil protrusion.

Previously, the NUMEN® range – including NUMEN® Frame, NUMEN® Fill, and NUMEN® Finish - obtained HAS approval and reimbursement codes in April and October 2023, respectively. This significant advancement aims to alleviate patient financial burdens and expedite market acceptance in France, benefiting more patients.

NUMEN® was approved for marketing in China in September 2020. It also holds CE MDR approval in Europe, FDA approval in the United States, MFDS approval in Korea, ANVISA approval in Brazil, and MHLW approval in Japan. NUMEN® features 177 specifications of varying lengths and diameters, allowing for precise treatment tailored to different aneurysm cases through a minimally invasive approach. It aims to thrombose aneurysms over the medium to long term while mitigating risks associated with open surgery. Its ultra-fine platinum-tungsten coil and unique 3D structure offer a combination of flexibility and support, suitable for treating aneurysms of diverse shapes.

MicroPort

MicroPort® NeuroTech™ Completes World's First Application of PCAR Intervention System

Recently, the Percutaneous Neuroprotection for Carotid Artery Remodelling (PCAR) Intervention System, jointly developed by MicroPort® NeuroTech™ in collaboration with Prof. Bo Yu's team at Fudan University Pudong Medical Center, achieved a global milestone with the completion of the world's first PCAR procedure at the center. This successful intervention rescued a patient suffering from severe carotid artery stenosis. The PCAR represents an evolution from Transcarotid Artery Revascularization (TCAR), further advancing minimally invasive techniques and simplifying operations.

Inspired by TCAR, MicroPort® NeuroTech™ and Prof. Bo Yu 's team successfully developed the PCAR system which allows for device placement through a simple puncture, thus making the procedure even less invasive. Moreover, PCAR serves as an important path and adjunct method for the endovascular intervention of cerebrovascular ischemic diseases.

Prof. Bo Yu remarked, "The successful procedure demonstrates that PCAR can be a vital method for the interventional treatment of cerebrovascular ischemic diseases. PCAR has opened a new pathway for interventional treatment of cerebrovascular diseases and has established a new platform for carotid and cerebrovascular interventions, which allows for further advancements in treatment capabilities, such as intravascular carotid plaque ablation to achieve EndoCEA."

Investor Newsletter

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
First Vice President of Board Secretary and Legal Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com